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Abstract
Objective: To study differences in adherence to common inhaled medications in COPD.
Methods: Adherence of 795 patients was recorded from pharmacy records over 
3 years in the COMIC cohort. It was expressed as percentage and deemed good 
at ≥75–≤125%, sub-optimal ≥50–<75%, and poor <50% (underuse) or >125% 
(overuse). Most patients used more than one medication, so we present 1379 
medication periods.
Results: The percentages of patients with good therapy adherence ranged from 43.2 
(beclomethasone) – 75.8% (tiotropium); suboptimal from 2.3 (budesonide) – 23.3% 
(fl uticasone); underuse from 4.4 (formoterol/budesonide) – 18.2% (beclomethasone); 
and overuse from 5.1 (salmeterol) – 38.6% (budesonide). Patients using fl uticasone 
or salmeterol/fl uticasone have a 2.3 and 2.0-fold increased risk of suboptimal versus 
good adherence compared to tiotropium. Patients using salmeterol/fl uticasone 
or beclomethasone have a 2.3- and 4.6-fold increased risk of underuse versus 
good adherence compared to tiotropium. Patients using budesonide, salmeterol/
fl uticasone, formoterol/budesonide, ciclesonide and beclomethasone have an 
increased risk of overuse versus good adherence compared to tiotropium. Adherence 
to inhalation medication is inversely related to lung function. 
Conclusion: Therapy adherence to inhalation medication for the treatment of COPD 
is in our study related to the medication prescribed. Tiotropium showed the highest 
percentage of patients with good adherence, followed by ciclesonide, both dosed 
once daily. The idea of improving adherence by using combined preparations 
cannot be confi rmed in this study. Further research is needed to investigate the 
possibilities of improving adherence by changing inhalation medication.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a major cause of chronic 
morbidity and mortality throughout the world. In general, the treatment of 
COPD is supportive, aimed at relieving patients symptoms, to decrease the 
number of exacerbations, and to improve quality of life (1). Bronchodilators 
are the key element in pharmacological management of COPD (1). In addition, 
since pulmonary infl ammation is prominent in COPD (2), anti-infl ammatory 
drugs such as inhaled corticosteroids are often used.
Th e eff ectiveness of inhaled medications is strongly infl uenced by the 
patient’s drug adherence. Adherence to medication has been shown to be 
associated with reduced risk of death and hospitalization (3).
Medication adherence is infl uenced by patient and medication related 
factors. Critical patient related factors for optimal medication adherence 
in patients with COPD are patients’ disease and treatment acceptance, 
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 knowledge about and faith in the treatment, eff ective 
patient-clinician relationship, and routinisation of 
drugtherapy (4–6). Medication related factors such 
as frequent daily use and multiple dosing have both 
shown to have a negative infl uence on adherence (7).
Patients with COPD often use a medication regimen 
requiring multiple daily dosages during a prolonged 
period and often use diff erent medications simultane-
ously. All these factors combined can make therapy 
adherence for COPD patients a diffi  cult task.
Nonadherence to inhalation medication can be 
divided in several categories. Th e use of medication has 
to start with obtaining the medication. After obtaining 
the patient can underuse, overuse or show improper use 
(for example forgetfulness and alteration of schedules 
and doses) of the medication (4,8). 
A specifi c problem with inhalation medication is the 
use of the device in which the medication is adminis-
tered. Improving inhalation technique can improve 
adherence (9).
Medication adherence with regard to maintenance 
medication in patients with COPD is generally poor, 
varying in medication database studies from 28–40% for 
inhalation corticosteroids, 29–35% for  corticosteroid/ 
sympaticomimetic combinations and 54–61% for long-
acting sympaticomimetics and tiotropium (10–12).
Many adherence studies use data of one-year follow-
up and cannot discriminate between asthma and COPD 
patients (11,13,14). Medication use in COPD is long 
term. We therefore conducted a study to investigate 
therapy adherence with inhalation medication over a 
period of 3 years in a well-defi ned cohort of confi rmed 
COPD-patients to give an estimate on long-term use. 
Methods
Setting and design
Th is study is part of the Cohort of Mortality and Infl am-
mation in COPD (COMIC) study a single-centre pro-
spective cohort study. From December 2005 until April 
2010, 795 patients were included with a follow-up period 
of 3 years. Patients were recruited at the outpatient clinic 
of the Department of Pulmonology, Medisch Spectrum 
Twente Hospital, Enschede, located in the Eastern part 
of Th e Netherlands, serving a catchment population of 
approximately 264,000 persons. Th e study was approved 
by the hospital’s Medical Ethical Committee (P05–49). 
All patients provided written informed consent.
To be eligible for the study patients had to meet the 
following criteria; (1) a clinical diagnosis of COPD, as 
defi ned by the GOLD criteria (2) current or ex-smoker; 
(3) age 40 years or over; (4) no medical condition com-
promising survival within the follow-up period or seri-
ous psychiatric morbidity, and (5) absence of any other 
active lung disease (eg, sarcoïdosis), (6) no maintenance 
therapy with antibiotics, (7) and the ability to speak 
Dutch. Patients were consecutively enrolled when hos-
pitalised for an acute exacerbation of COPD (AECOPD 
group) or when visiting the outpatient clinic in stable 
state (stable state group).
To be included in the AECOPD group, patients had 
to be hospitalised for an AECOPD and be able to pro-
duce an adequate sputum sample at the day of hospitali-
sation. To be included in the stable state group patients 
had to meet the following criteria: no use of antibiotic 
and/or prednisolone 4 weeks prior to enrolment and no 
exacerbation less than 4 weeks before study entry. Of the 
1503 patients that were screened for eligibility, a total of 
795 were included. All surviving patients completed the 
three-year follow-up period. All patients were treated 
according to standard care. Demographic data was 
 collected from medical records. 
Lung function and smoking status were both deter-
mined at baseline. Lung function was measured by 
spirometry, performed according to standardised guide-
lines (15). Forced Expiratory Volume in 1 sec (FEV1)
and Vital Capacity (VC) were measured until three 
reproducible recordings (less than 5% diff erence) were 
obtained. Smoking status was determined by the Vlagt-
wedde questionnaire (16).
Th e primary outcome, therapy adherence, was 
recorded from patients’ pharmacy records. Th e patients 
were not aware that their medication records were going 
to be used for the monitoring of therapy adherence. 
Th eoretical duration of exposure was calculated using 
information on dispensing date, total supply, and dos-
age regimen. We computed the total number of days for 
which patients had collected medication during follow-
up and divided this by the total number of days between 
the fi rst and last medication collection during follow up 
plus the day’s supply of the last refi ll (17).
Th is was expressed as a percentage and adherence 
was deemed good if it was ≥75–≤125%, sub-optimal 
between ≥50–<75%, and poor below <50% (underuse) 
or above >125% (overuse). In literature there is no con-
sensus on acceptable therapy adherence, defi nitions 
vary from >70% to >80% for a clinical research setting. 
We decided to set the limit for optimal adherence at ≥75, 
which is between these two defi nitions. Next to this, 
we decided to choose an upper cut-off  point as well for 
optimal adherence (>125%), in order to exclude overuse 
from this category (3,10,11,18). We excluded medica-
tion when it was prescribed once only or was used less 
than 90 days.
Computerized pharmacy data made it feasible to 
monitor medication adherence by tracking requests for 
refi lls. Computerized drug dispensing histories from 
Dutch pharmacies are virtually complete and include 
data concerning the dispensed drug, the prescriber, the 
dispensing date, the amount dispensed, the prescribed 
dose regimens, and the estimated duration of use. In 
Th e Netherlands, there is a strong pharmacy-patient 
liaison for reimbursement of prescription drugs, a high 
degree of computerization, the use of standardized clas-
sifi cation and coding systems, and a strong commitment 
of pharmacists to surveillance of medication.
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Th e following bronchodilators were used: salmeterol 
and tiotropium. Furthermore, the inhaled cortico-
steroids beclomethasone, ciclesonide, fl uticasone and 
budesonide and the combined preparations of fl uti-
casone/salmeterol and budesonide/formoterol were 
included in the analyses. Th erapy adherence with for-
moterol was not analysed, because formoterol (unlike 
salmeterol) can be used on demand as well and this 
confounds our calculation of adherence (19).
Statistical analyses
Baseline characteristics are reported as mean with SD 
for continuous variables, or as numbers with corre-
sponding percentages for categorical or dichotomous 
variables. Not normally distributed continuous vari-
ables are reported as median with corresponding inter-
quartile range (IQR).
We investigated the relationship between therapy 
adherence and type of medication with Nominal Regres-
sion analyses. Tiotropium and good therapy adherence 
were set as reference in the Nominal Regression analyses.
Furthermore potential confounders (age, sex, smok-
ing status, lung function) were fi rst tested for their asso-
ciation with therapy adherence. Associated variables 
were subsequently tested for their association with type 
of medication. For categorical variables this association 
was tested by means of Chi-square tests or Fisher exact 
tests, as appropriate. For continuous variables this asso-
ciation was tested with an ANOVA or Kruskal–Wallis 
test as appropriate. 
Variables that were both associated with therapy 
adherence and type of medication were all entered in 
the multivariate Nominal Regression analyses. Subse-
quently, potentially confounding variables with the high-
est p-value were eliminated from the model one by one 
until the fi t of the model decreased signifi cantly, based 
on the –2 Log Likelihood.
All statistical calculations were carried out with the 
SPSS statistical package (version 21.0) and p-values 
<0.05 were considered signifi cant.
Results
Th e study population included 795 patients (Table 1). 
Patients were predominantly male (61.1%). Th e mean 
age of the study population was 68 years. Almost three-
quarters of the patients were ex-smokers. 
Table 2 displays the number (%) of patients in the 
subgroups of therapy adherence for the diff erent inha-
lation medications. Because many patients used more 
than one type of inhaled medication and since use of 
one medication in diff erent devices (for example MDI 
and Diskus) was scored separately during the observa-
tion period, data on 1379 periods of medication use 
are presented. Th e majority of the study patients were 
treated with tiotropium and salmeterol/fl uticasone. 
Th e percentages of patients with good therapy 
 adherence within the studied medications ranged from 
43.2 (beclomethasone) – 75.8% (tiotropium); subopti-
mal adherence ranged from 2.3 (budesonide) – 23.3% 
(fl uticasone); underuse from 0 (ciclesonide) – 18.2% 
(beclomethasone); and overuse from 5.1 (salmeterol) 
– 38.6% (budesonide). All inhaled medications had 
a median time of use of more than 25 months except 
beclomethasone (15) and ciclesonide (23.5). Th e Chi-
square test showed an association between therapy 
adherence and the studied medications (p < 0.001).
To compare the four categories of therapy adher-
ence between inhalation medications we used Nominal 
Regression analyses. Because the highest percentage of 
patients with good adherence was observed for tiotro-
pium, this medication, including good therapy adher-
ence was set as reference in Table 3.
Of the potential confounders listed in Table 1, FEV1
in litres, FEV1 % predicted and FEV1/VC ratio were both 
associated with type of medication as well as with ther-
apy adherence and were therefore potential confound-
ers that should be entered to the multivariate Nominal 
Regression analyses. Due to multicolinearity between 
FEV1 in litres, FEV1 % predicted and FEV1/VC ratio, 
only the variable with the best model fi t was entered to 
multivariate Nominal Regression analyses, which was 
FEV1 in litres. 
Compared to tiotropium, patients using fl utica-
sone or salmeterol/fl uticasone had a 2.3- and 2.0-fold 
increased risk of suboptimal versus good adherence 
(Table 3). Patients using salmeterol/fl uticasone or 
beclomethasone had a 2.3- and 4.6-fold increased risk 
of underuse versus good adherence. Patients using 
budesonide, beclomethasone, formoterol/budesonide, 
Table 1. Baseline characteristics
N = 795
Overall
Good
≥75–≤125%
Sub-optimal 
≥50–<75%
Underuse 
<50%
Overuse 
>125% P
Age in years (Mean (SD)) 67.8 (9.9) 66.5 (9.6)   66.5 (10.3) 64.3 (11.0) 67.2 (9.7) 0.100
Sex (Number of men (%))   486 (61.1)   560 (61.6)  112 (53.6) 62 (53.9) 87 (59.6) 0.102
Smoking status (Number (%))
 Current smoker
 Ex-smoker
  212 (26.7)
  583 (73.3)
  246 (27.1)
  663 (72.9)
   49 (23.4)
  160 (76.6)
45 (39.1)
70 (60.9)
56 (38.4)
90 (61.6)
0.001
Lung function (Mean (SD))
 FEV 1 in Litres
 FEV1 % predicted
 FEV1/VC ratio
 1.4 (0.6)
52.1 (19.4)
44.5 (13.6)
 1.4 (0.6)
51.0 (17.8)
42.3 (12.6)
 1.4 (0.5)
52.4 (18.4)
45.5 (13.3)
1.5 (0.6)
55.3 (20.1)
48.0 (15.2)
1.3 (0.5)
47.3 (16.9)
42.3 (12.7)
0.001
0.004
0.000
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ciclesonide and salmeterol/fl uticasone, beclometha-
sone had an increased risk of  overuse versus good 
adherence. 
Compared to fl uticasone as reference medication, 
budesonide had a 0.12 fold risk of suboptimal use 
compared to optimal use; budesonide, formoterol/
budesonide and beclomethasone had an increased risk 
of overuse (6.1, 3.1 and 4.8, respectively) compared 
to optimal use, and beclomethasone had a 4.3-fold 
increased risk of underuse. 
FEV1(L) at baseline was related to poor adherence, 
both underuse and overuse.
Underuse was associated with a higher FEV1 at base-
line compared to good adherence, while overuse was 
associated with a lower FEV1 at baseline compared to 
good adherence.
Discussion
Th erapy adherence to inhalation medication for the 
treatment of COPD is in our study related to the medi-
cation prescribed. Th e medications dosed once daily, 
tiotropium and ciclesonide, showed the highest per-
centage of patients with good adherence. Medication 
dosed one time daily is a known factor that improves 
adherence. Adherence declines as the number of daily 
doses increased (20).
Th e percentage of patients with good adherence with 
tiotropium is high (76%) compared to literature. Ismaila 
et al. found that 61.1% and 62.9% of the tiotropium 
users showed good adherence (12). Also for corticoste-
roids and corticosteroids combined with adrenergics 
high percentages of good adherence were observed 
in our study (varying between 59 and 68%). Krigsman 
et al. found that only 28 and 29% of the patients showed 
good adherence for corticosteroids and corticosteroids 
combined with adrenergics (11). Vestbo et al. found 
that 79.8% of the patient showed good adherence with 
salmeterol, fl uticasone propionate or a combination of 
these two over a study period of 3 years. However, these 
patients were aware that their therapy adherence was 
being monitored and they had to bring all inhalers at 
every visit to exchange them for new ones (3).
All three studies used 80% as cut-off  point for good 
adherence. Changing the cut-off  in our study to 80% 
did not infl uence the “good” adherence levels (data not 
shown). Just as Krigsman did, we decided to choose an 
upper cut-off  point as well, in order to study overuse, 
another form of therapy nonadherence.
Th erapy adherence in a clinical trial setting is usually 
higher because patients are motivated by the clinical 
setting. In the COMIC study patients were not aware 
that their medication records were going to be used for 
the monitoring of therapy adherence. We therefore do 
Table 2. Number (%) of patients in the subgroups of therapy adherence per medication
Medication
Good
≥75–≤125%
Suboptimal
≥50–<75%
Underuse
<50%
Overuse 
>125%
Months used 
median (IQR)
Tiotropium (n=566) 429 (75.8) 68 (12.0) 36 (6.4) 33 (5.8) 28.7 (15.1–35.5)
Ciclesonide (n=22)  15 (68.2)  3 (13.6)  0  4 (18.2) 23.5 (15.8–35.5)
Salmeterol (n=39)  26 (66.7)  6 (15.4)  5 (12.8)  2 (5.1) 27.1 (6.9–35.2)
Fluticasone (n=73)  46 (63.0) 17 (23.3)  4 (5.5)  6 (8.2) 25.7 (12.5–34.9)
Formoterol/Budesonide (n=91)  56 (61.5) 12 (13.2)  4 (4.4) 19 (20.9) 31.2 (15.9–36.5)
Salmeterol/Fluticasone (n=500) 295 (59.0) 95 (19.0) 55 (11.0) 55 (11.0) 27.5 (13.7–35.0)
Budesonide (n=44)  23 (52.3)  1 (2.3)  3 (6.8) 17 (38.6) 28.2 (17.4–36.7)
Beclomethasone (n=44)  19 (43.2)  7 (15.9)  8 (18.2) 10 (22.7) 15.7 (7.5–31.7)
Table 3. Nominal regression analyses of medication vs. therapy adherence
OR 95% CI
Suboptimal (≥50–<75%) (n=209) FEV1 (L) baseline 1.1 0.8–1.4
Ciclesonide 1.3 0.4–4.4
Salmeterol 1.4 0.6–3.6
Fluticasone 2.3 1.3–4.3
Formoterol/Budesonide 1.4 0.7–2.7
Salmeterol/Fluticasone 2.0 1.4–2.9
Budesonide 0.3 0.04–2.1
Beclomethasone 2.3 0.9–5.7
Underuse (<50%) n=115) FEV1 (L) baseline 1.5 1.1–2.1
Ciclesonide ** **
Salmeterol 2.1 0.8–5.9
Fluticasone 1.1 0.4–3.2
Formoterol/Budesonide 0.8 0.3–2.4
Salmeterol/Fluticasone 2.3 1.5–3.6
Budesonide 1.6 0.4–5.5
Beclomethasone 4.6 1.9–11.3
Overuse (>125%) (n=145)*** FEV1 (L) baseline 0.6 0.4–0.8
Ciclesonide 3.6 1.1–11.6
Salmeterol 0.5 0.1–4.1
Fluticasone 1.6 0.6–4.0
Formoterol/Budesonide 4.9 2.6–9.3
Salmeterol/Fluticasone 2.3 1.5–3.7
Budesonide 9.8 4.7–20.2
Beclomethasone 7.7 3.3–18.1
*Good adherence and tiotropium were set as reference. All corrected for FEV1 in Litres (L) 
at baseline.
**Not possible to calculate.
***One missing due to missing lung function data.
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not expect a large infl uence on therapy adherence as 
observed by patients participating in a clinical trial set-
ting. In this light the therapy adherence levels found in 
our study can be considered very high. Th is is in line 
with a nationwide observational study that showed 
higher adherence levels in our region compared to other 
regions in the Netherlands (21).
Th is study showed increased risks of suboptimal 
adherence, underuse and overuse for investigated 
inhaled corticosteroids and corticosteroid/sympatico-
mimetic combinations compared to tiotropium with 
optimal adherence.
Th ese diff erences can be caused by medication 
related factors as number of daily doses needed or relief 
of symptoms. Tiotropium relieves dyspnea whereas cor-
ticosteroids do not give immediate relief (22). Th e ques-
tion is whether changing inhalation medication within 
the same class of medication can improve therapy 
adherence. For example if a patient shows underuse on 
beclomethasone would changing therapy to fl uticasone 
improve adherence? Th is should be evaluated in future 
studies. Furthermore, could the diff erence in therapy 
adherence also be related to the device in which inhala-
tion medication is administered?
Another interesting fi nding is that the idea of improv-
ing adherence by using combined preparations cannot 
be confi rmed in this study. Diff erences in adherence 
between the inhaled corticosteroids and the combined 
preparations lie in the levels of over- and underuse. 
Adherence is signifi cantly higher in some prepara-
tions and numerically but not statistically signifi cant in 
 others. Combining inhalation medication in one device 
is thought to improve adherence. 
Yet, guidelines for the treatment of COPD (GOLD, 
Dutch guidelines of NHG and CBO) do not recommend 
the use of combined preparations to improve therapy 
adherence (23,24). Our study supports this view. Given 
the observational design of the study it is however pos-
sible that the combined preparations were given to 
patients that had problems with therapy adherence on 
the sole preparations, thus resulting in an apparently 
greater rate of adherence in the remaining subjects con-
tinuing to use the sole preparations. Similar results were 
found for the treatment of asthma in children as well as 
adults (25).
Th erapy adherence to inhalation medication showed 
to be related to FEV1 at baseline. Underuse was associ-
ated with a higher FEV1 at baseline, while overuse was 
associated with a lower FEV1 at baseline. It is possible 
that patients with higher FEV1 feel less need to use their 
medication and therefore show lower adherence levels. 
Th e opposite can be an explanation for overuse with a 
lower FEV1. Turner et al found a relation between good 
adherence and reduced FEV1. Th is is in line with our 
results (26).
Th ere are some potential limitations in our study. 
Th erapy adherence can be measured in several ways. Most 
common are the use of collected pharmacy records, ques-
tionnaires or interviews. Pharmacy records give an indica-
tion of drug refi ll patterns but not of the actual inhalation. 
Patients can decide to collect the medication to appear 
adherent, but can dump the medication at home (27). 
Another problem with regard to the calculation of adher-
ence is that the prescriber can change the dosage regimen 
without giving a new prescription. Th e pharmacy records 
do not refl ect the actual use at this point. Th e data show 
the maximum levels of drug use among the patients, and 
it is likely that the inhaled drug volumes are lower than 
the volumes dispensed by the pharmacy (28,29).
We excluded medication if it was prescribed only 
once or for a period of less than 90 days in a period of 
3 years. One time only records give no information on 
therapy adherence. Due to our defi nition a one-time pre-
scription fi ll scores 100% therapy adherence. Th is would 
distort our results. We studied therapy adherence over a 
period of three years. Short time use defi ned as 90 days 
or less was also excluded. In the Netherlands dispens-
ing medication for chronic use is restricted to 90 days or 
less. Th is rule was designed to reduce costs by preventing 
discarding large amounts of unused drugs. Patients that 
do not persist with new inhalation medications, a form 
of failing therapy adherence, were thereby excluded. 
In our data a patient using one inhalation medica-
tion is registered as two separate episodes, when the 
inhalation medication is used in two diff erent devices. 
Although a similar adherence could possibly be expected 
when patients use the same medication in a diff erent 
inhaler, our data showed that this is often not the case 
(data not shown). Th erefore, we decided not to combine 
the episodes to an overall adherence but to use the sepa-
rate episodes. Next to the above mentioned limitations 
we were not able to investigate the eff ects of improving 
adherence by changing inhalation medication due to the 
observational character of the study.
Despite these limitations, major advantages of this 
study compared with previous published studies are the 
possibility to link adherence to lungfunction. Although 
other studies with pharmacy data alone lack the pos-
sibility to discriminate between asthma and COPD, our 
patients were all diagnosed with COPD. Many adher-
ence studies use data of one-year follow-up. Medication 
use in COPD is long term. We followed our patients for 
3 years, thus giving an estimate on long-term use. 
Conclusion
Th erapy adherence to inhalation medication for the 
treatment of COPD is related to the medication pre-
scribed. Th is study also confi rms that dosing a medica-
tion one time daily improves adherence and adherence 
to inhalation medication is related to lung function. 
Th erefore, lung function should be taken into account 
when therapy adherence is assessed. Th e assump-
tion that combining two inhalation medications in 
one device can improve therapy adherence cannot be 
 confi rmed. Further research is needed to investigate the 
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possibilities of improving adherence by changing inha-
lation medication.
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